Key facts
- This page summarizes Vered Bisker-Leib's Form 4 filing for Ayala Pharmaceuticals, Inc..
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 23 Jan 2023, 17:17.
Vered Bisker-Leib - 19 Jan 2023 Form 4 Insider Report for Ayala Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 19 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jan 2023, 17:17:33 UTC
- Prior SEC filing
- 25 Nov 2022
- Next SEC filing
- 09 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vered Bisker-Leib
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vered Bisker-Leib filed Form 4 for Ayala Pharmaceuticals, Inc. on 23 Jan 2023.
Change
- Previous filing in this sequence was filed on 25 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADXS
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +1,639
- Change %
- Price
- Shares after
- 1,639
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,639
- Exercise price
- $58.59
- Footnotes
- F1, F2
ADXS
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +1,171
- Change %
- Price
- Shares after
- 1,171
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,171
- Exercise price
- $55.23
- Footnotes
- F3, F4
ADXS
transaction
Derivative
Stock Option
Award
- Transaction value
- Shares
- +1,171
- Change %
- Price
- Shares after
- 1,171
- Date
- 19 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,171
- Exercise price
- $8.69
- Footnotes
- F5, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
The option vests and becomes exercisable in thirty-six substantially equal monthly installments, such that the option shall be fully vested on August 18, 2023.
Footnote F2
Received in the merger of Ayala Pharmaceuticals, Inc. ("Old Ayala") into the Issuer (the "Merger") in exchange for an employee stock option to acquire 8,750 shares of the common stock of Old Ayala for $10.98 per share.
Footnote F3
This option is fully vested and exercisable.
Footnote F4
Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $10.35 per share.
Footnote F5
This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
Footnote F6
Received in the Merger in exchange for an employee stock option to acquire 6,250 shares of the common stock of Old Ayala for $1.63 per share.